Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$85.87 +0.4%	$78.56	$61.24 ▼ $86.57	$265.14B	0.36	5.13 million shs	3.49 million shs
JNJ Johnson & Johnson	$188.95 +0.4%	$177.04	$140.68 ▼ $189.92	$453.15B	0.4	8.70 million shs	8.69 million shs
MRNA Moderna	$27.34 -0.7%	$26.06	$23.15 ▼ $59.73	$10.76B	2.01	12.29 million shs	6.06 million shs
PFE Pfizer	$26.27 -0.6%	$24.76	$20.92 ▼ $30.43	$150.27B	0.55	62.68 million shs	47.61 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+0.21%	+15.32%	+4.64%	+22.09%	+10.35%
JNJ Johnson & Johnson	-0.15%	+3.63%	+5.63%	+20.85%	+17.43%
MRNA Moderna	-3.33%	+8.72%	+9.55%	-15.37%	-54.25%
PFE Pfizer	-3.34%	+10.95%	+6.42%	+3.28%	-7.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$85.87 +0.4%	$78.56	$61.24 ▼ $86.57	$265.14B	0.36	5.13 million shs	3.49 million shs
JNJ Johnson & Johnson	$188.95 +0.4%	$177.04	$140.68 ▼ $189.92	$453.15B	0.4	8.70 million shs	8.69 million shs
MRNA Moderna	$27.34 -0.7%	$26.06	$23.15 ▼ $59.73	$10.76B	2.01	12.29 million shs	6.06 million shs
PFE Pfizer	$26.27 -0.6%	$24.76	$20.92 ▼ $30.43	$150.27B	0.55	62.68 million shs	47.61 million shs

10 Best Stocks to Own: Fall 2025

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+0.21%	+15.32%	+4.64%	+22.09%	+10.35%
JNJ Johnson & Johnson	-0.15%	+3.63%	+5.63%	+20.85%	+17.43%
MRNA Moderna	-3.33%	+8.72%	+9.55%	-15.37%	-54.25%
PFE Pfizer	-3.34%	+10.95%	+6.42%	+3.28%	-7.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	2.80	Moderate Buy	$86.00	0.15% Upside
JNJ Johnson & Johnson	2.68	Moderate Buy	$189.88	0.49% Upside
MRNA Moderna	2.00	Hold	$41.81	52.94% Upside
PFE Pfizer	2.37	Hold	$28.41	8.15% Upside

Current Analyst Ratings Breakdown

Latest MRNA, JNJ, PFE, and AZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/7/2025	JNJ Johnson & Johnson	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $213.00
10/6/2025	JNJ Johnson & Johnson	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$172.00 ➝ $193.00
10/3/2025	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$198.00
10/3/2025	JNJ Johnson & Johnson	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Equal Weight ➝ Overweight	$170.00 ➝ $212.00
10/3/2025	JNJ Johnson & Johnson	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$170.00 ➝ $212.00
10/3/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$175.00 ➝ $198.00
10/3/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$28.00 ➝ $30.00
10/1/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$28.00
9/30/2025	JNJ Johnson & Johnson	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$188.00 ➝ $210.00
9/27/2025	AZN AstraZeneca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy (B)
9/27/2025	JNJ Johnson & Johnson	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)

(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.93	$6.32 per share	13.58	$13.18 per share	6.52
JNJ Johnson & Johnson	$88.82B	5.12	$13.18 per share	14.34	$29.69 per share	6.36
MRNA Moderna	$3.24B	3.30	N/A	N/A	$28.33 per share	0.97
PFE Pfizer	$63.63B	2.35	$4.33 per share	6.06	$15.62 per share	1.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.66	32.28	17.17	1.57	14.68%	32.84%	12.87%	11/11/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$9.35	20.21	17.07	2.40	25.00%	32.49%	13.00%	10/14/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.97	8.67	0.86	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest MRNA, JNJ, PFE, and AZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2025	Q3 2025	PFE Pfizer	$0.79	N/A	N/A	N/A	$16.94 billion	N/A
10/14/2025	Q3 2025	JNJ Johnson & Johnson	$2.78	N/A	N/A	N/A	$23.73 billion	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
7/29/2025	Q2 2025	AZN AstraZeneca	$1.09	$1.09	N/A	$0.79	$14.08 billion	$14.46 billion
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.68	$2.77	+$0.09	$2.29	$22.85 billion	$23.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$1.01	1.18%	N/A	37.97%	N/A
JNJ Johnson & Johnson	$5.20	2.75%	N/A	55.61%	64 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.55%	N/A	91.49%	16 Years

Latest MRNA, JNJ, PFE, and AZN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/16/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.35%	8/26/2025	8/26/2025	9/9/2025
7/29/2025	AZN AstraZeneca	semi-annual	$0.5050	2%	8/8/2025	8/8/2025	9/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.55	0.86	0.67
JNJ Johnson & Johnson	0.50	1.01	0.76
MRNA Moderna	N/A	3.93	3.77
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
JNJ Johnson & Johnson	0.16%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRNA Moderna	5,800	390.58 million	346.28 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

MRNA, JNJ, PFE, and AZN Headlines

Recent News About These Companies

Life sciences sentiment rises as Pfizer deal eases tariff concerns

October 7 at 12:32 PM | proactiveinvestors.com

Down 50%, Should You Buy the Dip on Pfizer?

October 7 at 10:10 AM | fool.com

Down 50%, Should You Buy the Dip on Pfizer?

October 7 at 10:03 AM | fool.com

TrumpRx Brings Pfizer Into the Green-Is It a Buy?

October 7 at 9:37 AM | msn.com

Why The Pfizer-Trump Pharma Deal Is A Win For Branded Pharma, But Not For Consumers

October 7 at 9:11 AM | talkmarkets.com

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? (Revised)

October 7 at 8:16 AM | zacks.com

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

...

October 7 at 7:04 AM | marketbeat.com

Hiltzik: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer

October 7 at 6:30 AM | latimes.com

KLP Kapitalforvaltning AS Purchases 289,900 Shares of Pfizer Inc. $PFE

October 7 at 6:29 AM | marketbeat.com

SteelPeak Wealth LLC Has $6.24 Million Stake in Pfizer Inc. $PFE

October 7 at 5:33 AM | marketbeat.com

Belpointe Asset Management LLC Has $2.92 Million Stock Holdings in Pfizer Inc. $PFE

October 7 at 5:06 AM | marketbeat.com

Merit Financial Group LLC Has $5.04 Million Stock Holdings in Pfizer Inc. $PFE

October 7 at 4:34 AM | marketbeat.com

Pfizer Inc. $PFE Stake Cut by Simplicity Wealth LLC

October 7 at 4:22 AM | marketbeat.com

Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500

October 7 at 3:15 AM | fool.com

Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)

October 7 at 2:31 AM | seekingalpha.com

Pfizer (NYSE:PFE) Shares Down 3.4% - Time to Sell?

October 6 at 11:00 PM | marketbeat.com

Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal (PFE)

...

October 6 at 7:34 PM | marketbeat.com

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

...

October 6 at 2:21 PM | marketbeat.com

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

October 6 at 1:11 PM | zacks.com

3 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years

October 6 at 12:04 PM | 247wallst.com

3 High-Yield Dividend Stocks to Buy in October

October 6 at 10:32 AM | 247wallst.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MRNA, JNJ, PFE, and AZN Company Descriptions

AstraZeneca NASDAQ:AZN

$85.87 +0.38 (+0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$86.00 +0.13 (+0.15%)

As of 07:58 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Johnson & Johnson NYSE:JNJ

$188.95 +0.79 (+0.42%)

Closing price 03:59 PM Eastern

Extended Trading

$187.68 -1.27 (-0.67%)

As of 07:52 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$27.34 -0.20 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$27.30 -0.04 (-0.13%)

As of 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$26.27 -0.16 (-0.61%)

Closing price 03:59 PM Eastern

Extended Trading

$26.26 0.00 (-0.02%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRNA, JNJ, PFE, and AZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRNA, JNJ, PFE, and AZN Earnings

Compare Dividends

Latest MRNA, JNJ, PFE, and AZN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRNA, JNJ, PFE, and AZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRNA, JNJ, PFE, and AZN Company Descriptions

AstraZeneca NASDAQ:AZN

Johnson & Johnson NYSE:JNJ

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools